# A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Source: https://onco.cc/trials/nct07475806/  
OnCo record `nct07475806` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Enfortumab vedotin and Pembrolizumab in bladder & urothelial cancer, run by Astellas Pharma Global Development, Inc., now recruiting.

## Summary

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder is a phase 2 interventional study registered as NCT07475806 by Astellas Pharma Global Development, Inc., with 240 participants planned, started 2026-03-12 and due to reach its primary completion in 2027-11-30. Interventions recorded: Enfortumab Vedotin and Pembrolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07475806
- Phase: 2
- Setting: An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin Plus Pembrolizumab for Bladder Preservation in Participants With Muscle-invasive Bladder Cancer (EV-209)
- Sponsor: Astellas Pharma Global Development, Inc.
- Enrolled: 240

## Sources

- ClinicalTrials.gov NCT07475806: https://clinicaltrials.gov/study/NCT07475806

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Enfortumab vedotin](https://onco.cc/drugs/enfortumab-vedotin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Astellas](https://onco.cc/companies/astellas/), [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct07475806.json